The CRIF1–CDK2 interface inhibitors show benefits to the specificity and selectivity of treatment because they target CRIF1 and CDK interfaces, thus indirectly modulating the cell cycle and apoptosis and increasing the cancer cell sensitivity to chemotherapy. Here, CDK2 is linked to cancer.